Join
Live feed
·
PRReleasevia Quantisnow
Stoke Therapeutics Inc. logo

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
STOK· Stoke Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.) and more on Quantisnow.